Actinium Pharmaceuticals (ATNM) said Monday it signed a supply agreement with Eckert & Ziegler for Actinium-225.
Financial details weren't disclosed.
Under the agreement, Actinium Pharmaceuticals will access Eckert & Ziegler's high-quality Actinium-225 to advance Actimab-A and other development candidates for US and international clinical trials.
Ac-225 targeted radiotherapy offers precise cancer treatment by delivering high-energy alpha particles with minimal penetration. Actimab-A is an Ac-225-based therapy that specifically targets CD33, a receptor overexpressed in acute myeloid leukemia and other myeloid disorders, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.